Articles

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis

Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre
Department of Medicine, University of California at San Francisco, San Francisco, CA
Department of Hematology, University of Nantes, Nantes
Perth Blood Institute, Murdoch University, Perth
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
Department of Hematology, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul
Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers Cedex
Department of Hematology, Hôpital Saint-Antoine, Sorbonne University, INSERM UMRs 938, Paris
Hospital Universitario Virgen del Rocio, Sevilla
Department of Hematology, Ondokuz Mayıs University Faculty of Medicine, Samsun
Hôpital Maisonneuve-Rosemont, Université de Montréal
Sanofi Research and Development, Vitry/Alfortville
Aixial, Boulogne-Billancourt
Sanofi Research and Development, Vitry/Alfortville
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens
Haematologica Early view Oct 14, 2021 https://doi.org/10.3324/haematol.2021.279229